# Investment Dossier: SRPT
**Rank: #5 | Composite Score: 7.67/10**
**Generated: 2026-01-05 (as-of date)**

## Executive Summary
- Company: Sarepta Therapeutics, Inc.
- Price: $21.07
- Market Cap: $2.21B
- Cash: $613M
- Clinical Stage: commercial
- Active Trials: 10/50

## Score Breakdown

| Component | Score | Weight | Contribution |
|-----------|-------|--------|--------------|
| Stage | 10.0/10 | 30% | 3.00 |
| Cash (capped) | 8.4/10 | 25% | 2.10 |
| Runway | 6.0/10 | 25% | 1.50 |
| Pipeline | 5.3/10 | 20% | 1.07 |
| **Composite** | **7.67/10** | 100% | **7.67** |

## Financial Reality Check
- Cash: $613M
- Estimated Runway: ~16mo
- Market Cap: $2.21B
- Daily Volume: 2,798,757 shares

## Freshness & Point-in-Time Discipline

**As-of Date:** 2026-01-05

**SEC Financial Data:**
- Period End: 2025-10-01
- Period End Age: 96 days
- Filed Date: 2026-01-05
- Status: FRESH (<365 days)

**Market Data:**
- Source: Yahoo Finance (real-time)
- Last Update: 2026-01-05

## Data Quality
- Overall Coverage: 93%
- Financial Coverage: 100%
- SEC Data Status: Fresh

## Risk Warnings
- [WATCH] Runway < 18 months - monitor for financing

---
*Point-in-time validated. Algorithmically generated. Verify all data before investment decisions.*
